[
  {
    "ts": null,
    "headline": "Frank Sands Reduces Stake in DexCom Inc by 50.4%, Impacting Portfolio by -1.25%",
    "summary": "Insightful Analysis of Frank Sands (Trades, Portfolio)' Third Quarter 2025 13F Filing",
    "url": "https://finnhub.io/api/news?id=28f2cb7098f78da59290e358b310cf84e440777efc8c22fae42e325c9fa63a91",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763056970,
      "headline": "Frank Sands Reduces Stake in DexCom Inc by 50.4%, Impacting Portfolio by -1.25%",
      "id": 137470277,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "Insightful Analysis of Frank Sands (Trades, Portfolio)' Third Quarter 2025 13F Filing",
      "url": "https://finnhub.io/api/news?id=28f2cb7098f78da59290e358b310cf84e440777efc8c22fae42e325c9fa63a91"
    }
  },
  {
    "ts": null,
    "headline": "The Wild Ride That Sent IBD Stock Of The Day Insulet Into An Early Breakout",
    "summary": "Insulet is Thursday's IBD Stock Of The Day. After a wild post-earnings reaction, Insulet stock is in a consolidation with an early entry.",
    "url": "https://finnhub.io/api/news?id=d951e193bc58bdda2c01205faa22e576b04b2c41b5b35220f4f5fd1916730f7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763053564,
      "headline": "The Wild Ride That Sent IBD Stock Of The Day Insulet Into An Early Breakout",
      "id": 137470135,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "Insulet is Thursday's IBD Stock Of The Day. After a wild post-earnings reaction, Insulet stock is in a consolidation with an early entry.",
      "url": "https://finnhub.io/api/news?id=d951e193bc58bdda2c01205faa22e576b04b2c41b5b35220f4f5fd1916730f7f"
    }
  },
  {
    "ts": null,
    "headline": "Legal and Regulatory Scrutiny Over Device Changes Might Change the Case for Investing in DexCom (DXCM)",
    "summary": "Recently, multiple class action lawsuits were filed against DexCom, Inc. after reports surfaced alleging the company made unauthorized design changes to its G6 and G7 continuous glucose monitoring devices, resulting in potential reliability and safety issues and prompting regulatory scrutiny, including a warning letter from the FDA. This legal and regulatory attention grew after reports linked the device changes to health risks, hospitalizations, and deaths, prompting intensified market...",
    "url": "https://finnhub.io/api/news?id=532058b9ba76fbb1a7b8b4fe830a21bbbe4a0f7e27bd3a7aeb8edea50acc9a72",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763046821,
      "headline": "Legal and Regulatory Scrutiny Over Device Changes Might Change the Case for Investing in DexCom (DXCM)",
      "id": 137469398,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "Recently, multiple class action lawsuits were filed against DexCom, Inc. after reports surfaced alleging the company made unauthorized design changes to its G6 and G7 continuous glucose monitoring devices, resulting in potential reliability and safety issues and prompting regulatory scrutiny, including a warning letter from the FDA. This legal and regulatory attention grew after reports linked the device changes to health risks, hospitalizations, and deaths, prompting intensified market...",
      "url": "https://finnhub.io/api/news?id=532058b9ba76fbb1a7b8b4fe830a21bbbe4a0f7e27bd3a7aeb8edea50acc9a72"
    }
  },
  {
    "ts": null,
    "headline": "DexCom Stock: Is Wall Street Bullish or Bearish?",
    "summary": "Although DexCom stock has trailed the broader market over the past year, analysts remain bullish about its prospects.",
    "url": "https://finnhub.io/api/news?id=35170d16e1cf2c25c60c860c61a5a75e624fce4a6fb1ea9d93519712cad41715",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763033993,
      "headline": "DexCom Stock: Is Wall Street Bullish or Bearish?",
      "id": 137469399,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "Although DexCom stock has trailed the broader market over the past year, analysts remain bullish about its prospects.",
      "url": "https://finnhub.io/api/news?id=35170d16e1cf2c25c60c860c61a5a75e624fce4a6fb1ea9d93519712cad41715"
    }
  },
  {
    "ts": null,
    "headline": "Is It Time to Revisit DexCom After Latest Innovation Headlines?",
    "summary": "Ever wondered if DexCom is now a bargain or still priced for perfection? Let's get under the hood to see if the recent headlines match up with what the numbers are really saying. The stock has seen mixed momentum lately, climbing just 0.6% over the past week but still down 24.1% year-to-date and 17.8% in the past twelve months. This performance has put value-focused investors on alert. Recent news around DexCom's continued innovation in glucose monitoring technology has kept the company in...",
    "url": "https://finnhub.io/api/news?id=1d49b403bcbc1f7369b0381a9d69d5b363775138c8df3d7a9f29a5c5725ff038",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763032574,
      "headline": "Is It Time to Revisit DexCom After Latest Innovation Headlines?",
      "id": 137467376,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "Ever wondered if DexCom is now a bargain or still priced for perfection? Let's get under the hood to see if the recent headlines match up with what the numbers are really saying. The stock has seen mixed momentum lately, climbing just 0.6% over the past week but still down 24.1% year-to-date and 17.8% in the past twelve months. This performance has put value-focused investors on alert. Recent news around DexCom's continued innovation in glucose monitoring technology has kept the company in...",
      "url": "https://finnhub.io/api/news?id=1d49b403bcbc1f7369b0381a9d69d5b363775138c8df3d7a9f29a5c5725ff038"
    }
  },
  {
    "ts": null,
    "headline": "Winners And Losers Of Q3: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks",
    "summary": "Looking back on patient monitoring stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including DexCom (NASDAQ:DXCM) and its peers.",
    "url": "https://finnhub.io/api/news?id=ba6428d6a7f9b3832f19ae846cdf6b1f17bd3932a87fbc8b522624dabe99e7c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763004766,
      "headline": "Winners And Losers Of Q3: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks",
      "id": 137469400,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "Looking back on patient monitoring stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including DexCom (NASDAQ:DXCM) and its peers.",
      "url": "https://finnhub.io/api/news?id=ba6428d6a7f9b3832f19ae846cdf6b1f17bd3932a87fbc8b522624dabe99e7c4"
    }
  }
]